Analysis of Insulin Analogs and the Strategy of Their Further Development

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Biochemistry (Moscow)

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1134/S0006297918140122PMID 29544437
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Insulin analogues in type 1 diabetes mellitus: getting better all the time

  2017cited by this paper
• Characterization of Sizes of Aggregates of Insulin Analogs and the Conformations of the Constituent Protein Molecules: A Concomitant Dynamic Light Scattering and Raman Spectroscopy Study.

  2016cited by this paper
• Injectable insulin-lysozyme-loaded nanogels with enzymatically-controlled degradation and release for basal insulin treatment: In vitro characterization and in vivo observation.

  2016cited by this paper
• Insulin and Lispro Insulin: What is Common and Different in their Behavior?

  2016cited by this paper
• Pursuit of a perfect insulin

  2016cited by this paper
• Insulin amyloid at injection sites of patients with diabetes

  2016cited by this paper
• Blood-based signatures in type 1 diabetes

  2016cited by this paper
• [Premixed insulin and intermediate-acting insulin].

  2015cited by this paper
• BIOSIMILARS AND NEW INSULIN VERSIONS.

  2015cited by this paper
• CLINICAL AND ECONOMIC BENEFITS OF HUMAN INSULIN ANALOGUESUSE

  2015cited by this paper
• [Long-term administration of nucleos (t) ide analogues and HBV-DNA negativity].

  2015cited by this paper
• PEGylated insulin Lispro, (LY2605541)—a new basal insulin analogue

  2014cited by this paper
• Molecular Mechanisms of Insulin Resistance Development

  2014cited by this paper
• Pneumothorax recurrence related to high-speed lift.

  2014cited by this paper
• Diabetes mellitus and peripheral vascular disease: diagnosis and management.

  2014cited by this paper
• Suppressors of cytokine signaling (SOCS) and type 2 diabetes

  2014cited by this paper
• Challenges associated with insulin therapy in type 2 diabetes mellitus.

  2014cited by this paper
• Lower Glucose Variability and Hypoglycemia Measured by Continuous Glucose Monitoring With Novel Long-Acting Insulin LY2605541 Versus Insulin Glargine

  2014cited by this paper
• Basal Insulin Peglispro Demonstrates Preferential Hepatic Versus Peripheral Action Relative to Insulin Glargine in Healthy Subjects

  2014cited by this paper
• Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges?

  2014cited by this paper
• Insulin degludec/insulin aspart is the first co-formulation of basal and prandial insulin analogues

  2014cited by this paper
• Insulin glargine: pharmacokinetic and pharmacodynamic basis of clinical effect

  2014cited by this paper
• Insulin degludec is a new ultra-long-acting insulin analogue

  2014cited by this paper
• Basal insulin analogues in the management of diabetes mellitus: what progress have we made?

  2014cited by this paper
• Protective hinge in insulin opens to enable its receptor engagement

  2014cited by this paper
• Aromatic Anchor at an Invariant Hormone-Receptor Interface

  2014cited by this paper
• How to determine the size of folding nuclei of protofibrils from the concentration dependence of the rate and lag-time of aggregation. II. Experimental application for insulin and LysPro insulin: aggregation morphology, kinetics, and sizes of nuclei.

  2014cited by this paper
• Influence of miRNA in insulin signaling pathway and insulin resistance: micro‐molecules with a major role in type‐2 diabetes

  2014cited by this paper
• Type 1 diabetes.

  2014cited by this paper
• [Quality of life and problems posed by hypoglycemia in type 2 diabetes mellitus during oral hypoglycemic therapy].

  2013cited by this paper
• How insulin engages its primary binding site on the insulin receptor

  2013cited by this paper
• Elderly Patients with Diabetes Experience a Lower Rate of Nocturnal Hypoglycaemia with Insulin Degludec than with Insulin Glargine: A Meta-Analysis of Phase IIIa Trials

  2013cited by this paper
• How Hypoglycemia Impacts Quality of Life and Treatment Satisfaction in Type 2 Diabetes Mellitus Patients on Basal-Bolus Insulin Therapy?

  2013cited by this paper
• Mechanisms of insulin resistance in obesity

  2013cited by this paper
• Newer insulin analogs: advances in basal insulin replacement

  2013cited by this paper
• Basal insulin analogs: from pathophysiology to therapy. What we see, know, and try to comprehend?

  2013cited by this paper
• Influence of the dynamics of body weight on the risk factors of cardiovascular disease in patients with type 2 diabetes during the first year of insulin treatment

  2013cited by this paper
• The Emergence of Biosimilar Insulin Preparations—A Cause for Concern?

  2012cited by this paper
• Controlling the aggregation and rate of release in order to improve insulin formulation: molecular dynamics study of full-length insulin amyloid oligomer models

  2012cited by this paper
• Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin

  2012cited by this paper
• [Phylogenesis, etiology and pathogenesis of insulin resistance. Differences from type II diabetes mellitus].

  2012cited by this paper
• [Phylogenesis, etiology and pathogenesis of insulin resistance. Differences from type II diabetes mellitus].

  2012cited by this paper
• First phase insulin secretion and type 2 diabetes.

  2012cited by this paper
• The pharmacokinetics and pharmacodynamics of rapid‐acting insulin analogues and their clinical consequences

  2012cited by this paper
• Dissecting the role of disulfide bonds on the amyloid formation of insulin.

  2012cited by this paper
• Structural polymorphism and possible pathways of amyloid fibril formation on the example of insulin protein

  2012cited by this paper
• Intrinsic Fibrillation of Fast-Acting Insulin Analogs

  2012cited by this paper
• Formation of low-dimensional crystalline nucleus region during insulin amyloidogenesis process.

  2012cited by this paper
• The cancer genome: what's new?

  2011cited by this paper
• Insulin analogs for the treatment of diabetes mellitus: therapeutic applications of protein engineering

  2011cited by this paper
• Insulin detemir versus insulin glargine for type 2 diabetes mellitus.

  2011cited by this paper
• Pathway to diabetes through attenuation of pancreatic beta cell glycosylation and glucose transport

  2011cited by this paper
• Diagnosis and Classification of Diabetes Mellitus

  2011cited by this paper
• Insulin analogs versus human insulin in type 2 diabetes.

  2011cited by this paper
• Diagnosis and Classification of Diabetes Mellitus

  2011cited by this paper
• An Achilles' Heel in an Amyloidogenic Protein and Its Repair

  2010cited by this paper
• Supramolecular Protein Engineering

  2010cited by this paper
• Dinamika massy tela u bol'nykh sakharnymdiabetom 2 tipa v techenie pervogo godainsulinoterapii

  2010cited by this paper
• Review on the In Vitro Interaction of Insulin Glargine with the Insulin/Insulin-like Growth Factor System: Potential Implications for Metabolic and Mitogenic Activities

  2010cited by this paper
• Implications for the active form of human insulin based on the structural convergence of highly active hormone analogues

  2010cited by this paper
• Insulin and its analogs: actions via insulin and IGF receptors

  2010cited by this paper
• Formation mechanism of insulin fibrils and structural aspects of the insulin fibrillation process.

  2009cited by this paper
• Effect of N-methylation of selected peptide bonds on the biological activity of insulin. [2-N-methylisoleucine-A]insulin and [3-N-methylvaline-A]insulin.

  2009cited by this paper
• The solution structure of a superpotent b‐chain‐shortened single‐replacement insulin analogue

  2008cited by this paper
• [Gene engineered insulin and its pharmaceutical analogs].

  2008cited by this paper
• Secondary nucleation and accessible surface in insulin amyloid fibril formation.

  2008cited by this paper
• Structure-specific effects of protein topology on cross-beta assembly: studies of insulin fibrillation.

  2006cited by this paper
• Beta cell compensation for insulin resistance in Zucker fatty rats: increased lipolysis and fatty acid signalling

  2006cited by this paper
• The importance of redox shuttles to pancreatic beta-cell energy metabolism and function.

  2006cited by this paper
• Early Events in the Fibrillation of Monomeric Insulin*

  2005cited by this paper
• Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects.

  2005cited by this paper
• Efficacy and safety of insulin glulisine in patients with type 1 diabetes.

  2005cited by this paper
• Insulin and its receptor: structure, function and evolution.

  2004cited by this paper
• Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes.

  2004cited by this paper
• The protofilament structure of insulin amyloid fibrils

  2002cited by this paper
• Malonyl-CoA signaling, lipid partitioning, and glucolipotoxicity: role in beta-cell adaptation and failure in the etiology of diabetes.

  2002cited by this paper
• Structural biology of insulin and IGF1 receptors: implications for drug design

  2002cited by this paper
• Genetics of type 1A diabetes.

  2001cited by this paper
• Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin.

  2001cited by this paper
• Formation of insulin amyloid fibrils followed by FTIR simultaneously with CD and electron microscopy

  2000cited by this paper
• Role of NADH shuttle system in glucose-induced activation of mitochondrial metabolism and insulin secretion.

  1999cited by this paper
• Crystal structure of a prolonged-acting insulin with albumin-binding properties.

  1997cited by this paper
• Toward understanding insulin fibrillation.

  1997cited by this paper
• Physicochemical basis for the rapid time‐action of LysB28ProB29‐insulin: Dissociation of a protein‐ligand complex

  1996cited by this paper
• Prandial Glycaemia After a Carbohydrate‐rich Meal in Type I Diabetic Patients: Using the Rapid Acting Insulin Analogue [Lys(B28), Pro(B29)] Human Insulin

  1996cited by this paper
• Role of C-terminal B-chain residues in insulin assembly: the structure of hexameric LysB28ProB29-human insulin.

  1995cited by this paper
• Increased secretory demand rather than a defect in the proinsulin conversion mechanism causes hyperproinsulinemia in a glucose-infusion rat model of non-insulin-dependent diabetes mellitus.

  1995cited by this paper
• A spectroscopic investigation of the conformational dynamics of insulin in solution.

  1995cited by this paper
• [Lys(B28), Pro(B29)]-Human Insulin: A Rapidly Absorbed Analogue of Human Insulin

  1994cited by this paper
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

  1993cited by this paper
• Altering the association properties of insulin by amino acid replacement.

  1992cited by this paper
• Implications of invariant residue LeuB6 in insulin-receptor interactions.

  1991cited by this paper
• Genetic control of autoimmunity in type 1 diabetes.

  1990cited by this paper
• Intensive Insulin Therapy for Treatment of Type I Diabetes

  1990cited by this paper
• Perturbation of insulin-receptor interactions by intramolecular hormone cross-linking. Analysis of relative movement among residues A1, B1, and B29.

  1989cited by this paper
• The structure of 2Zn pig insulin crystals at 1.5 A resolution.

  1988cited by this paper
• Monomeric insulins obtained by protein engineering and their medical implications

  1988cited by this paper
• Altered Hand Skin Blood Flow in Type 1 (Insulin‐dependent) Diabetes Mellitus

  1988cited by this paper
• Studies on the molecular organization of rat insulin secretory granules.

  1987cited by this paper
• Phenol-promoted structural transformation of insulin in solution.

  1987cited by this paper

• Investigation of new non-toxic inhibitors of fibril formation and preservatives for insulin preparations its analogues.

  2025cites this paper
• The Effects of Naturally Occurring Phenols on Amyloid Fibrils from Insulin in the Liquid Phase Using Atomic Force Microscopy

  2025cites this paper
• Structural, kinetic, and thermodynamic aspects of insulin aggregation.

  2023cites this paper
• Molecular Aspects of Insulin Aggregation and Various Therapeutic Interventions

  2022cites this paper
• Progress in Simulation Studies of Insulin Structure and Function

  2022cites this paper
• A new fibrillization mechanism of β-lactoglobulin in glycine solutions

  2022cites this paper
• Comparative Analysis of Aggregation of Thermus thermophilus Ribosomal Protein bS1 and Its Stable Fragment

  2020cites this paper
• Determination of amyloid core regions of insulin analogues fibrils

  2020cites this paper
• Identification of Amyloidogenic Regions in the Spine of Insulin Fibrils

  2019cites this paper
• Development and In Vitro Evaluation of Linear PEI-Shelled Heparin/Berberine Nanoparticles in Human Osteosarcoma U-2 OS Cells

  2018cites this paper
• The Institute of Protein Research of the Russian Academy of Sciences Is 50 Years Old

  2018cites this paper